Premium
A randomized trial of coenzyme Q 10 in mitochondrial disorders
Author(s) -
Glover Elisa I.,
Martin Joan,
Maher Amy,
Thornhill Rebecca E.,
Moran Gerald R.,
Tarnopolsky Mark A.
Publication year - 2010
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.21758
Subject(s) - cardiorespiratory fitness , medicine , lean body mass , vo2 max , endocrinology , randomized controlled trial , coenzyme q – cytochrome c reductase , mitochondrial myopathy , mitochondrion , chemistry , blood pressure , biochemistry , heart rate , cytochrome c , body weight , mitochondrial dna , gene
Abstract Case reports and open‐label studies suggest that coenzyme Q 10 (CoQ 10 ) treatment may have beneficial effects in mitochondrial disease patients; however, controlled trials are warranted to clinically prove its effectiveness. Thirty patients with mitochondrial cytopathy received 1200 mg/day CoQ 10 for 60 days in a randomized, double‐blind, cross‐over trial. Blood lactate, urinary markers of oxidative stress, body composition, activities of daily living, quality of life, forearm handgrip strength and oxygen desaturation, cycle exercise cardiorespiratory variables, and brain metabolites were measured. CoQ 10 treatment attenuated the rise in lactate after cycle ergometry, increased (∽1.93 ml) V O 2 /kg lean mass after 5 minutes of cycling ( P < 0.005), and decreased gray matter choline‐containing compounds ( P < 0.05). Sixty days of moderate‐ to high‐dose CoQ 10 treatment had minor effects on cycle exercise aerobic capacity and post‐exercise lactate but did not affect other clinically relevant variables such as strength or resting lactate. Muscle Nerve, 2010